SmartCare Dyslipidemia: Prevent the 1st Event

Introduction

Take This Event

- Introduction to Dyslipidemia Burden & Gaps
- LDL-C Reduction Guidelines and Targets
- Use of PCSK9i in Very High Risk Patients with Diabetes

Objectives

By the end of the activity, participants will be able to apply the latest dyslipidemia treatment guidelines to at least 90% of their patients, as demonstrated by post-activity quizzes or case study discussions.
By the end of the activity, 85% of participants will demonstrate the ability to identify high-risk patients for dyslipidemia-related cardiovascular events using lipid panel results and patient history during a case-based discussion.
Within one month of completing the activity, participants will report at least a 20% improvement in their ability to communicate the benefits and risks of dyslipidemia treatment to patients, as measured by follow-up surveys.
By the end of the activity, participants will be able to design a comprehensive treatment plan, incorporating both pharmacological and non-pharmacological interventions, for at least 80% of the case studies provided.

Speaker

Dr. Metab Algefari

Consultant Diabetologist, Dr. Suliman Alhabib Hospital, Buraydah

DR. Mohamed Salah El-Din

Consultant Internal Medicine, King’s College Hospital, Jeddah

Dr .Mohammed ALBasara

Consultant Endocrinologist and Internist

Sponsored by :